trending Market Intelligence /marketintelligence/en/news-insights/trending/x48g7kzu6pnikwr2lcnwmw2 content esgSubNav
In This List

Bristol-Myers CEO's compensation rises to $18.7M in 2017


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Bristol-Myers CEO's compensation rises to $18.7M in 2017

Bristol-Myers Squibb Co. paid CEO Giovanni Caforio about $18.7 million in total remuneration in 2017, up from about $16.9 million in 2016.

Caforio received almost $1.6 million in base salary and received compensation of almost $3.9 million from ?non-equity incentive plan, or incentive awards, the company stated in an SEC filing.

That compares to about $1.5 million in base salary and almost $3.0 million in compensation from the non-equity incentive plan in 2016.

The New York-based pharmaceutical's CEO, who is also the company's board chairman, received $12.7 million from stock awards in comparison to $11.8 million in the year-ago period.

Caforio's market, or payout, value of unearned shares from outstanding equity awards at the end of fiscal 2017 stands at $7.4 million.

The ratio of Caforio's annual total compensation compared to Bristol-Myers' median employee's total annual compensation for fiscal year 2017 is 169 to 1, or about $18.7 million compared to $110,280, respectively.